Long noncoding RNA endogenous bornavirus-like nucleoprotein acts as an oncogene by regulating microRNA-655-3p expression in T-cell acute lymphoblastic leukemia

Jinhua Yang and Yingying Yang

Department of Hematology, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

ABSTRACT

Acute lymphocytic leukemia (ALL) is the most common malignant tumor in children with T-cell ALL (T-ALL), accounting for approximately 15% of all cases. Long noncoding RNAs (lncRNAs) are involved in the pathogenesis and progression of T-ALL. The present study aimed to explore the role and mechanism of action of lncRNA EBLN3P in T-ALL. We used quantitative reverse transcription-PCR (qRT-PCR) to determine the expression of lncRNA endogenous bornavirus-like nucleoprotein (EBLN3P), microRNA (miR)-655-3p, and the transcription level of matrix metalloproteinase-9 (MMP-9), and Western blot assay to quantify the protein expression level of cleaved-caspase 3, caspase 3, proliferating cell nuclear antigen (PCNA), and MMP-9. The potential binding sites between lncRNA EBLN3P and miR-655-3p were predicted using StarBase, and the interaction was further verified by dual-luciferase reporter assay and RNA pull-down assay. The proliferation ability of Jurkat cells was detected using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, and their invasion and migration ability using transwell assay. Cell apoptosis was determined using flow cytometry (FCM) assay. The expression of lncRNA EBLN3P was upregulated while that of miR-655-3p was downregulated in human T-ALL cell lines and lncRNA EBLN3P negatively regulated miR-655-3p. LncRNA EBLN3P knockdown significantly inhibited proliferation, invasion, and migration of Jurkat cells and induced their apoptosis. Downregulating miR-655-3p reversed the effects of lncRNA EBLN3P knockdown on Jurkat cells. In conclusion, we confirmed for the first time that lncRNA EBLN3P is dysregulated in T-ALL cell lines, and lncRNA EBLN3P knockdown inhibited the malignant biological behaviors of T-ALL cells by up-regulating miR-655-3p.

CONTACT Yingying Yang yy1051128@163.com  Department of Hematology, Wuhan Fourth Hospital, 473 Hanzheng Street, Qiaokou District, Wuhan, Hubei 430033, China

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
**Introduction**

T-cell acute lymphoblastic leukemia (T-ALL) is a hematologic malignancy characterized by malignant hematopoietic cells that diffusely infiltrate the bone marrow and other tissues [1]. T-ALL accounts for 15% and 25% of all ALL cases in children and adults, respectively [2,3]. According to the different stages of T cell differentiation in the thymus, T-ALL can be divided into pro-T-, pre-T-, cortical-T-, and medullary-T-ALL [4]. Earlier reports indicated that mature T-ALL (cortical T-ALL) had a better prognosis than the immature T-ALL (pro/pre-T-ALL) [5,6]; however, modern chemotherapy and minimal residual disease (MRD)-based risk stratification have rendered the stage of development without prognostic significance. Early precursor T-cell acute lymphoblastic leukemia (ETP-ALL) was recognized as a new provisional entity of ALL by the World Health Organization (WHO) in 2016, with unique immunophenotypes and genetic characteristics [7]. Approximately 70% of pediatric and 50% of adult T-ALL patients achieve a long-term complete remission with intensive treatment regimens [8–10]. However, the prognosis for patients with relapsed T-ALL remains poor – one-third of patients suffer from recurrent disease, and the 5-year overall survival rate (OS) for adults is approximately 50%–55% [11,12]. Since n-arabin, approved in 2005, no new drugs have been specifically approved for relapsed T-ALL. The blast of proliferation and survival advantages of T-ALL cells arose from changes in signaling pathways [13].

Long noncoding RNAs (lncRNAs) are the largest subclass of noncoding RNAs ubiquitous in eukaryotic cells. LncRNAs are over 200 nucleotides in length and lack an open reading frame [14,15]. They regulate gene expression and participate in various cell signaling pathways by interacting with DNA, RNA, or proteins [16,17]. LncRNAs involved in cancer signaling pathways play important roles in tumor suppression or growth [18]. Transcriptome analysis has shown that LncRNAs exhibit highly specific spatiotemporal expression patterns of lineage across different tissues and cell types [19,20]. Increasing evidence has shown that LncRNAs are dysregulated in various cancers. Wang et al. revealed that 826 lncRNAs were abnormally expressed in bladder cancer, three of which were closely related to the OS of patients [21]. Liu et al. identified 145 LncRNAs to be abnormally expressed in esophageal cancer (ESCA), of which eight LncRNAs were associated with OS in ESCA patients [22]. Thus, LncRNAs could be used as reliable biomarkers and therapeutic targets to achieve more effective cancer treatments. The prominent types of LncRNAs have a common function – to regulate gene expression by sponging miRNAs [23,24]. LncRNA bornavirus-like nucleoprotein (LncRNA EBLN3P) has been reported to be abnormally expressed in various cancers. Dai et al. noted that LncRNA EBLN3P was overexpressed in osteosarcoma tissues and cell lines and promoted osteosarcoma progression by sponging miR-224-5p [25]. Li et al. revealed that LncRNA EBLN3P could promote the progression of liver cancer by competitively sponging miR-144-3p [26]. A study by Jiang et al. revealed that LncRNA EBLN3P promoted the recovery of damaged spiral ganglion neurons by competitively binding with miR-204-5p [27]. In breast cancer, the expression of LncRNA EBLN3P was downregulated, and its expression was related to better prognosis of OS and longer progression-free interval (PFI) [28]. Increasing evidence indicates that LncRNAs are associated with the pathogenesis and progression of T-ALL. The LncRNA CDKN2B-AS1 is upregulated in pediatric T-ALL peripheral blood mononuclear cells and promotes T-ALL development [29]. LncRNA NRIL was significantly upregulated in T-ALL samples, and its downregulation significantly inhibited the malignant biological behavior of T-ALL cells [30]. To date, the role of LncRNA EBLN3P in T-ALL has not been clarified.

LncRNAs can act as microRNA (miRNA) sponges, reducing their regulatory effect on miRNAs [31]. miRNAs are a class of noncoding RNAs (~22 nts) that could negatively regulate their target genes [32]. Bioinformatics analysis found that there are hundreds of miRNAs that bind to LncRNA EBLN3P, including miR-655-3p. Interestingly, miR-655-3p has been shown to participate in the occurrence and progression of many cancers, such as ovarian cancer, non-small cell lung cancer, and hepatocellular carcinoma [33–35], with its expression downregulated in all these.
cancers. The role of miR-655-3p in T-ALL has not been reported, but its expression is abnormally decreased in acute myeloid leukemia (AML) cells. MiR-655-3p silencing reversed the cytarabine (Ara-C)-induced proliferation inhibition and apoptosis promotion [36].

In the present study, we hypothesized that IncRNA EBLN3P plays a cancer-promoting role in T-ALL through regulating miR-655-3p expression. Therefore, in this study, we investigated the expression of IncRNA EBLN3P in human T-ALL cell lines and its role in the progression of T-ALL and its molecular mechanism.

**Materials and methods**

**Clinical samples**

22 cases clinical samples were obtained from Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology from April 2020 to April 2021. 22 cases of blood samples were obtained from 22 T-ALL patients (age range, 4–28 years; 11 males, 11 females) and 22 healthy donors (age range, 3–32 years; 11 males, 11 females). The present study was approved by the Ethical Review Committee of Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology. Written informed consents were obtained from all of the patients or legal guardians.

**Cell culture**

The human T-ALL cell line (TALL-1, KOPTK1, Jurkat, CCRF-CEM) and human peripheral blood mononuclear cells (PBMCs) were purchased from the Department of Cell Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (Beijing, China). All cells were grown in RPMI-1640 medium (Thermo, cat no. 11,875,093) supplemented with 10% FBS (Fetal Bovine Serum; Thermo, cat no. 10,100,147), and incubated in a humidified atmosphere at 37°C and 5% CO₂.

**Quantitative reverse transcription PCR (qRT-PCR)**

Total RNA was extracted using Beyotime (cat no. R0011) reagent. We collected 5 × 10⁶ cells, resuspended and lysed them with 100 μl Beyozzo reagent, added 20 μl chloroform, and incubated them for 3 min at room temperature. The supernatant obtained by centrifugation was mixed with 50 μl isopropanol and incubated for 10 min at room temperature. Finally, total RNA was precipitated using centrifugation and dissolved in RNase-free water, and its concentration was determined for later use. Quantitative reverse transcription PCR (qRT-PCR) was performed using the BeyoFast™ SYBR Green One-Step qRT-PCR Kit (cat no. D7286S). The reaction mixture was prepared according to the manufacturer’s instructions, and the experiment was performed using an Applied Biosystems 7500 Fast real-time PCR system. We used small nucleolar RNA U6 and GAPDH as internal controls for RNA and gene expression, respectively. Data for each sample was normalized to that of U6 or GAPDH. Relative quantification was performed using the 2⁻ΔΔCt method [37]. Primer sequences were obtained from Sangon Biotech (Shanghai, China) and listed as following:

- GAPDH forward, 5'-CATCATCCCTGCTC TACTTG-3'; reverse, 5'-GGGTGTCGCGTGT TT GAAGTC-3';
- U6 S, 5'-GGAACGATACAGAGA GATTAGC-3'; Stem-loop-R, 5'-CTCAAATGGT GTCGTGGAGTC-3';
- MPM-9 forward, 5'-TCCCC ATCGCCATCCC-3'; reverse, 5'-CACCATGG CCTGGGCTTG-3'; IncRNA EBLN3P forward, 5'-CAGACTAAAGGATCAGGGA-3'; reverse, 5'-ATCAATTCCACAGGGTGAA-3';
- miR-655-3p forward, 5'-CAATCTAAGGATCAGGGA-3'; reverse, 5'-GTGTCTTAAAGGCTAGGC CTA-3'.

**Dual-luciferase reporter assay**

The interaction between IncRNA EBLN3P and miR-655-3p was verified using a dual-luciferase reporter assay in vitro [38]. The wild type and mutant sequences of IncRNA EBLN3P were cloned downstream of the luciferase gene promoter (PGL3-IncRNA EBLN3P-wt or PGL3-IncRNA EBLN3P-mut). A dual-luciferase reporter assay was performed using HEK293T cells. Before transfection, HEK293T cells were inoculated into 12-well plates at 50% confluence and cultured for 16 h. Then, the cells were co-transfected with
PGL3-lncRNA EBLN3P-wt, PGL3-lncRNA EBLN3P-mut, and miR-655-3p mimic or mimic control for 48 h. Luciferase activity was measured using a luciferase reporter assay kit (Abcam, cat no. ab228530).

**RNA pull-down assay**

The interaction between lncRNA EBLN3P and miR-655-3p was verified using an RNA pull-down assay in vitro [39]. Jurkat cells were collected and lysed using sonication. The lncRNA EBLN3P probe was biotinylated with Pierce™ RNA 3’-terminal biotinylation kit (Thermo, cat no. 20,160) and incubated with M-280 streptavidin magnetic beads (S3762, Sigma, USA) to generate probe-coated beads. The lncRNA EBLN3P probe-coated beads and oligo probe-coated beads were incubated with Jurkat cell lysis at 4°C overnight with the lncRNA EBLN3P anti-sense probe as a negative control. Finally, the bound RNA was eluted with a high-salt buffer solution, and miR-655-3p was quantified using RT-qPCR.

**Cell proliferation ability**

Cell proliferation was determined using an MTT assay kit (Abcam, cat no. ab211091) [40]. The transfected cells were seeded into 96-well plates at a density of 5 × 10^3 cells/well in 200 μl of culture medium and cultured for the indicated time (0, 24, 48, and 72 h). Then, the plates were centrifuged at 4°C at 1000 × g for 5 min in a microplate-compatible centrifuge, and the medium was replaced with a mixture of 50 μl serum-free media and 50 μl MTT reagent. The plates were cultured for 3 h and then centrifuged, and the MTT reagent-supplemented medium was removed. Finally, 150 μl MTT solvent was added to each well and incubated for 15 min at room temperature. Absorbance was measured at 570 nm wavelength.

**Western blot analysis**

The expression of proteins in Jurkat cells was determined using Western blotting [41]. Cells were washed with pre-cold PBS buffer, lysed with M-PER reagent (Thermo, cat no. 78,501) containing phosphatase and protease inhibitor cocktail (Thermo, cat no. 78,440), and centrifuged at 12,000 rpm for 40 min at 4°C. The supernatant with a total protein content of 20 μg was separated on 12% SDS-PAGE. The protein was transferred to PVDF membranes using an XCell SureLock Mini-Cell electrophoresis system (Thermo) and blocked with 5% nonfat dry milk in TBS for 1 h at room temperature. The membranes were then incubated with primary antibodies (Abcam; 1:500 for Anti-cleaved caspase-3, cat. no. ab2302; 1:5000 for Anti-caspase-3, cat. no. ab32351; 1:5000 for Anti-MMP-9, cat. no. ab76003; 1:5000 for Anti-PCNA, cat. no. ab92552; 1:2500 for Anti-GAPDH, cat. no. ab9485) and secondary antibodies (Abcam; 1:5000, cat. no. ab97080). The enhanced chemiluminescence method (Cytiva) was used to detect immune response bands.

**Flow cytometry (FCM) analysis of cell apoptosis**

Cell apoptosis was detected using the Annexin V-FITC/PI Apoptosis Detection Kit (GeneBio Systems, cat no. A211-01). In brief, 5 × 10^5 transfected Jurkat cells were collected and washed with pre-cold PBS buffer. The cells were re-suspended in 100 μl 1X binding buffer, and 5 μl Annexin V-FITC and 5 μl PI staining solution were added. The mixture was incubated at room temperature for 10 min in the dark. Finally, 400 μl 1X binding buffer was added and the cells were analyzed by flow cytometry using FACSCalibur (BD Biosciences) within 1 h of staining [42].

**Transwell assay**

The invasion and migration of Jurkat cells were determined by a transwell assay. In the cell invasion experiment, the processed Jurkat cells were collected and resuspended in a culture medium without FBS. Then, 200 μl cell suspension (containing 2 × 10^5 cells) was plated on the top chamber of a transwell plate coated with Matrigel (Merck, cat. no. CLS3422) and 500 μl of the medium containing 10% FBS was added to the lower chamber. The cells were then cultured for 24 h. After incubation, the medium was gently removed, and the cells in the lower chamber were fixed with 4% paraformaldehyde for 30 min. The cells were then stained with 0.1% crystal violet
for 20 min. Finally, the stained cells were observed and photographed using a confocal microscope. The procedure for the migration experiment was similar to that for the invasion experiment, except the plate was not coated with Matrigel [43].

**Statistical analysis**

In this study, all experiments were independently repeated more than three times. Data are expressed as the mean ± standard deviation. Unpaired t-test and one-way ANOVA were used to analyze two groups and multiple groups of data, respectively, using SPSS 19.0 (SPSS Inc., Chicago, IL). A P value of <0.05 was considered statistically significant.

**Results**

**LncRNA EBLN3P sponges miR-655-3p**

The interaction between miRNAs, mRNAs, circRNAs, and lncRNAs reveals the complex mechanism of the occurrence and development of various cancers. As the expression of lncRNA EBLN3P and miR-655-3p was dysregulated in T-ALL patients, we hypothesized that there was an interaction between lncRNA EBLN3P and miR-655-3p in T-ALL cells. The functional binding site for miR-655-3p on lncRNA EBLN3P was predicted using the biological prediction website (http://starbase.sysu.edu.cn/index.php) (Figure 1(a)). The interaction was further verified using dual-luciferase reporter assays and RNA pull-down assays. We first confirmed that, compared with the mimic control group, miR-655-3p mimic significantly enhanced miR-655-3p levels in 293 T cells (Figure 1(b)). The dual-luciferase reporter assay showed that miR-655-3p mimic transfection resulted in a significant decrease in luciferase activity of the PGL3-lncRNA EBLN3P-wt vector, but cells with the PGL3-lncRNA EBLN3P-mut vector remained unaffected (Figure 1(c)). In the RNA pull-down assay, miR-655-3p was significantly enhanced in the lncRNA EBLN3P probe-coated group compared with the oligo probe-coated group (Figure 1(d)).

**The expression of lncRNA EBLN3P and miR-655-3p in clinical samples and T-ALL cell lines**

LncRNAs EBLN3P and miR-655-3p participate in the development of various cancers. Therefore, we investigated the expression of lncRNA EBLN3P and miR-655-3p in clinical samples from healthy donors and T-ALL patients, and in T-ALL cell lines. Compared with the healthy samples, the levels of lncRNA EBLN3P in the patient samples were significantly upregulated, while the level of miR-655-3p significantly down-regulated (Figure 2(a, b)). The results of the qRT-PCR assay indicated that the expression of lncRNA EBLN3P was significantly upregulated in human T-ALL cell lines (TALL-1-1.96 fold, KOPTK1-2.33 fold, Jurkat-4.26 fold, and CCRF-CEM-3.19 fold) compared with the human peripheral blood mononuclear cells (PBMCs) (Figure 2(c)). The expression of miR-655-3p was downregulated in human T-ALL cell lines (TALL-1-0.58 fold, KOPTK1-0.45 fold, Jurkat-0.25 fold, and CCRF-CEM-0.37 fold) compared with normal blood samples and PBMCs.

---

*Figure 1. LncRNA EBLN3P sponges miR-655-3p.*

(A) The binding sites between lncRNA EBLN3P and miR-655-3p were predicted using StarBase (http://starbase.sysu.edu.cn/index.php). (B) The level of miR-655-3p in 293 T cells transfected with mimic control or miR-655-3p mimic was determined using qRT-PCR. (C) Dual-luciferase reporter assay was performed to verify the effects of miR-655-3p on the luciferase activity of PGL3-lncRNA EBLN3P-wt and PGL3-lncRNA EBLN3P-mut vectors. (D) RNA pull-down assay was used to determine the interaction between lncRNA EBLN3P and miR-655-3p *in vitro*. The results indicated that miR-655-3p could be pulled by beads coated with lncRNA EBLN3P probe but not the Oligo probe-coated beads. **p < 0.01 vs. Mimic control; ***p < 0.01 vs. Oligo probe.
The human T-ALL Jurkat cell line with the most obvious expression changes of lncRNA EBLN3P and miR-655-3p was selected for further study.

**miR-655-3p was negatively regulated by lncRNA EBLN3P in Jurkat cells**

To explore whether miR-655-3p was negatively regulated by lncRNA EBLN3P in Jurkat cells, Jurkat cells were transfected with control siRNA, lncRNA EBLN3P-siRNA, inhibitor control, miR-655-3p inhibitor, lncRNA EBLN3P-siRNA + inhibitor control, and lncRNA EBLN3P-siRNA + miR-655-3p inhibitor for 48 h. qRT-PCR was used to determine transfection efficiency. Compared with control siRNA, lncRNA EBLN3P-siRNA transfection significantly diminished lncRNA EBLN3P expression in Jurkat cells (Figure 3(a)). The expression of miR-655-3p was inhibited by the miR-655-3p inhibitor in Jurkat cells compared with the inhibitor control (Figure 3(b)). In lncRNA EBLN3P-siRNA transfected Jurkat cells, the expression of miR-655-3p was markedly increased, and this increase was reversed by the miR-655-3p inhibitor (Figure 3(c)).

**lncRNA EBLN3P-siRNA inhibits proliferation and induces apoptosis of Jurkat cells by upregulating miR-655-3p**

To investigate the role of lncRNA EBLN3P knock-down on the proliferation and apoptosis of Jurkat cells, Jurkat cells were transfected with control-siRNA, lncRNA EBLN3P-siRNA, lncRNA EBLN3P-siRNA + inhibitor control, and lncRNA EBLN3P-siRNA + miR-655-3p inhibitor for 48 h. Cell proliferation ability was determined using the MTT assay at the indicated time points (0, 24, 48, and 72 h). The results revealed that the
proliferation ability of Jurkat cells was significantly inhibited by lncRNA EBLN3P-siRNA transfection compared with control-siRNA transfection, while the inhibitory effect of lncRNA EBLN3P-siRNA transfection could be reversed by miR-655-3p inhibitor transfection (Figure 4(a)). The mRNA and protein expression of proliferating cell nuclear antigen (PCNA) were determined using qRT-PCR and Western blot assays, respectively. We observed a decreased mRNA and protein expression of PCNA in Jurkat cells after transfection with lncRNA EBLN3P-siRNA and lncRNA EBLN3P-siRNA co-transfected with miR-655-3p inhibitor rescued the mRNA and protein expression of PCNA (Figure 4(b,c)). Apoptosis of Jurkat cells was detected using flow cytometry (FCM) analysis. lncRNA EBLN3P-siRNA transfection significantly induced apoptosis of Jurkat cells compared to control siRNA, while co-transfection with miR-655-3p inhibitor inhibited the apoptosis induced by lncRNA EBLN3P-siRNA (Figure 4(d,e)). The expression of cleaved-caspase3 and caspase3 was determined using Western blotting. lncRNA EBLN3P-siRNA transfection obviously increased the protein expression of cleaved-caspase3 (Figure 4(f)) and the ratio of cleaved-caspase3/caspase3 (Figure 4(g)) in Jurkat cells compared to control-siRNA transfection, and this increase was reversed by co-transfection with miR-655-3p inhibitor.

**LncRNA EBLN3P-siRNA inhibits invasion and migration of Jurkat cells by upregulating miR-655-3p**

To study the role of lncRNA EBLN3P knockdown on the invasion and migration of Jurkat cells, Jurkat cells were transfected with control-siRNA, lncRNA EBLN3P-siRNA, lncRNA EBLN3P-siRNA + inhibitor control, and lncRNA EBLN3P-siRNA + miR-655-3p inhibitor for 48 h, and the transfection efficiency was determined using qRT-PCR. (A) lncRNA EBLN3P-siRNA transfection significantly decreased the expression of lncRNA EBLN3P in Jurkat cells compared with the control siRNA transfection. (B) Transfection with miR-655-3p inhibitor significantly decreased the expression of miR-655-3p in Jurkat cells compared with the cells transfected with the inhibitor control. (C) The expression of miR-655-3p was upregulated after transfection with lncRNA EBLN3P-siRNA, and the enhancement was reversed by co-transfection with miR-655-3p inhibitor. **p < 0.01 vs. Control-siRNA; ## p < 0.01 vs. inhibitor control; & &p < 0.01 vs. lncRNA EBLN3P-siRNA + inhibitor control. 

![Figure 3](image_url) **Figure 3.** MiR-655-3p was negatively regulated by lncRNA EBLN3P in Jurkat cells. 

Jurkat cells were transfected with control siRNA, lncRNA EBLN3P-siRNA, inhibitor control, miR-655-3p inhibitor, lncRNA EBLN3P-siRNA + inhibitor control, and lncRNA EBLN3P-siRNA + miR-655-3p inhibitor for 48 h, and the transfection efficiency was determined using qRT-PCR. (A) lncRNA EBLN3P-siRNA transfection significantly decreased the expression of lncRNA EBLN3P in Jurkat cells compared with the control siRNA transfection. (B) Transfection with miR-655-3p inhibitor significantly decreased the expression of miR-655-3p in Jurkat cells compared with the cells transfected with the inhibitor control. (C) The expression of miR-655-3p was upregulated after transfection with lncRNA EBLN3P-siRNA, and the enhancement was reversed by co-transfection with miR-655-3p inhibitor. **p < 0.01 vs. Control-siRNA; ## p < 0.01 vs. inhibitor control; & &p < 0.01 vs. lncRNA EBLN3P-siRNA + inhibitor control.
MMP-9 (Figure 5(e, f)), while co-transfection with miR-655-3p inhibitor abolished the inhibitory effects on MMP-9.

**Discussion**

Newly diagnosed T-ALL patients show improvement as the treatment progresses, including glucocorticoids, asparaginase, and central nervous system targeted therapy. However, the prognosis of patients with relapsed T-ALL remains poor [11,12,46]. Therefore, further study on the pathogenesis of T-ALL will be helpful in the early identification of the disease, discovery of new therapeutic targets, and development of more efficacious drugs to improve the prognosis of the patients.

Dysregulated lncRNAs involved in different regulatory mechanisms may serve as new biomarkers for distinguishing between ALL subgroups and determining the prognosis [47,48]. The lncRNA EBLN3P is dysregulated in many cancers, including osteosarcoma, liver, and breast cancers [25,26,28]. However, the role of EBLN3P in T-ALL remains unclear.

MiR-655-3p has been confirmed to be involved in the occurrence and development of various tumors [33–35]. For example, miR-655-3p inhibited proliferation and migration of ovarian cancer cells by targeting RAB1A [33]. miR-655-3p inhibits non-small cell lung cancer cell migration and invasion by targeting pituitary tumor-transforming 1 [34]. Besides, miR-655-3p plays a tumor
suppressor role in acute myeloid leukemia cells [36]. These results suggest that miR-655-3p may inhibit the proliferation, migration and invasion of T-ALL cells. As a prominent function of lncRNAs is to regulate gene expression by sponging miRNAs [23,24,49], we investigated the correlation between lncRNA EBLN3P and miR-655-3p in T-ALL cells. StarBase (http://starbase.sysu.edu.cn/index.php) predicted an interaction between lncRNA EBLN3P and miR-655-3p that was further confirmed by luciferase reporter assays and RNA pull-down assays. In this study, we found that the expression of lncRNA EBLN3P is upregulated in clinical samples of T-ALL patients and in human T-ALL cell lines, while miR-655-3p is downregulated in clinical samples of T-ALL patients and in human T-ALL cell lines.

We then conducted several experiments to explore the effects of miR-655-3p and lncRNA EBLN3P on the malignant biological behaviors of T-ALL cells. Dysregulated cell proliferation, together with inhibition of apoptosis, provides the minimal platform necessary to support further tumor progression [50]. Migration and invasion of cancer cells into surrounding tissue and vasculature is an important initial step in cancer metastasis, and metastasis is the leading cause of cancer related death [51]. In this study, the data indicated that EBLN3P knockdown significantly inhibited malignant biological behaviors (proliferation, invasion, and migration) and induced apoptosis of T-ALL cells, and all the effects induced by lncRNA EBLN3P knockdown could be reversed by downregulating miR-655-3p. Moreover, cell proliferation and apoptosis related markers PCNA and Caspase3, and metastasis related gene MMP-9 were determined. PCNA is an essential protein involved in multiple processes of DNA metabolism, and targeting PCNA has been shown to be an effective strategy to inhibit tumor cell proliferation [52]. Caspases are key mediators of apoptosis, and among them, caspase-3 is a frequently activated death protease that catalyzes the specific cleavage of many key cellular proteins.

Figure 5. LncRNA EBLN3P knockdown inhibits invasion and migration of Jurkat cells by upregulating miR-655-3p.
Jurkat cells were transfected with control-siRNA, lncRNA EBLN3P-siRNA, lncRNA EBLN3P-siRNA + inhibitor control, and lncRNA EBLN3P-siRNA + miR-655-3p inhibitor for 48 h. (A) and (B) Cell migration and (C) and (D) invasion were determined using a transwell assay. (E) and (F) Protein and mRNA expression of MMP-9 was detected using Western blot assay and qRT-PCR analysis. **p < 0.01 vs. Control-siRNA; ## p < 0.01 vs. LncRNA EBLN3P-siRNA + inhibitor control.
[53]. MMP-9 is a protease with a key role in tumor progression and metastasis [54]. Our findings indicated that IncRNA EBLN3P knockdown significantly decreased PCNA and MMP-9 expression, while enhanced cleaved-Caspase3 expression in T-ALL cells, and all these changes were significantly revised by miR-655-3p inhibitor.

However, we did not explore the more in-depth molecular mechanisms of the role of miR-655-3p in T-ALL cells (targets of miR-655-3p were not analyzed), and this was a limitation of the present study. We will perform this issue in the future.

Conclusion

Our study is the first to demonstrate that IncRNA EBLN3P is dysregulated in T-ALL, and IncRNA EBLN3P knockdown may inhibit the malignant biological behaviors of T-ALL cells by preventing the sponging of miR-655-3p, providing a new potential therapeutic target for T-ALL.

Data availability statement

All datasets used and/or generated during the current study are available from the corresponding author on reasonable request.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

The author(s) reported there is no funding associated with the work featured in this article.

References

[1] Gianni F, Belver L, Ferrando A. The genetics and mechanisms of T-Cell acute lymphoblastic leukemia. Cold Spring Harb Perspect Med. 2020;10:a035246.
[2] Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood. 2012;119:34–43.
[3] Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukemia: a subtype of very high-risk acute lymphoblastic leukemia. Lancet Oncol. 2009;10:147–156.
[4] Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias.
[5] European group for the immunological characterization of leukemias (EGIL). Leukemia. 1995;9:1783–1786.
[6] Yuan TT, Liu YR, Chang Y, et al. Characteristics of T-cell lineage immunophenotype in 95 patients with acute lymphoid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011;19:1134–1140.
[7] Jain N, Lamb AV, O’Brien S, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127:1863–1869.
[8] Arber DA, Orazi A, and Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
[9] Kochupillai V. Emerging concepts in the management of acute lymphoblastic leukaemia. Indian J Med Res. 1993;98:1–7.
[10] Onciu M. Acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23:655–674.
[11] Samra B, Jabbour E, Ravandi F, et al. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020;13:70.
[12] Hoelzer D, Gökgübet N. T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma. Clinical Lymphoma & Myeloma. 2009;9(3):S214–221.
[13] Bongiovanni D, Saccomani V, Piovan E. Aberrant signaling pathways in T-Cell Acute lymphoblastic leukemia. Int J Mol Sci. 2017;18:1904.
[14] Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:460–469.
[15] Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of IncRNAs. Adv Exp Med Biol. 2017;1008:1–46.
[16] Ulitsky I, Bartel DP. lncRNAs: genomics, evolution, and mechanisms. Cell. 2013;154:26–46.
[17] Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36:5661–5667.
[18] Dinescu S, Ignat S, Lazar AD, et al. Epitranscriptomic signatures in IncRNAs and their possible roles in cancer. Genes (Basel). 2019;10:52.
[19] Ward M, McEwan C, Mills JD, et al. Conservation and tissue-specific transcription patterns of long noncoding RNAs. J Hum Transcr. 2015;1:2–9.
[20] Li F, Xiao Y, Huang F, et al. Spatiotemporal-specific IncRNAs in the brain, colon, liver and lung of macaque during development. Mol Biosyst. 2015;11:3253–3263.
[21] Wang Y, Du L, Yang X, et al. A nomogram combining long non-coding RNA expression profiles and clinical
factors predicts survival in patients with bladder cancer. Aging (Albany NY). 2020;12:2857–2879.

[22] Liu H, Zhang Q, Lou Q, et al. Differential analysis of lncRNA, miRNA and mRNA Expression profiles and the prognostic value of lncRNA in Esophageal cancer. Pathol Oncol Res. 2020;26:1029–1039.

[23] Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the rosetta stone of a hidden RNA language? Cell. 2011;146:353–358.

[24] Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505:344–352.

[25] Dai S, Li N, Zhou M, et al. LncRNA EBLN3P promotes the progression of osteosarcoma through modifying the miR-224-5p/Rab10 signaling axis. Sci Rep. 2021;11: <yr>-1992</yr>. DOI: 10.1038/s41598-021-81641-6

[26] Li H, Wang M, Zhou H, et al. Long noncoding RNA EBLN3P promotes the progression of liver cancer via alteration of microRNA-144-3p/Dock4 signal. Cancer Manag Res. 2020;12:9339–9349.

[27] Jiang W, Peng A, Chen Y, et al. Long non-coding RNA EBLN3P promotes the recovery of the function of impaired spiral ganglion neurons by competitively binding to miR-204-5p and regulating TMPRSS3 expression. Int J Mol Med. 2020;45:1851–1863.

[28] Mathias C, Muzzi JCD, Antunes BB, et al. Unraveling immune-related lncRNAs in breast cancer molecular subtypes. Front Oncol. 2021;11:692170.

[29] Chen L, Shi Y, Li J, et al. LncRNA CDKN2B-AS1 contributes to tumorigenesis and chemoresistance in pediatric T-cell acute lymphoblastic leukemia through miR-335-3p/TRAF5 axis. Anticancer Drugs. 2020;25.

[30] Li G, Gao L, Zhao J, et al. LncRNA ANRIL/miR-7-5p/TCF4 axis contributes to the progression of T cell acute lymphoblastic leukemia. Cancer Cell Int. 2020;20:335.

[31] Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA Interactions. Methods Mol Biol. 2016;1402:271–286.

[32] Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141:1202–1207.

[33] Zha JF, Chen DX. MiR-655-3p inhibited proliferation and migration of ovarian cancer cells by targeting RAB1A. Eur Rev Med Pharmacol Sci. 2019;23:3627–3634.

[34] Wang W, Cao R, Su W, et al. miR-655-3p inhibits cell migration and invasion by targeting pituitary tumor-transforming 1 in non-small cell lung cancer. Biosci Biotechnol Biochem. 2019;83:1703–1708.

[35] Zhao XQ, Liang B, Jiang K, et al. Down-regulation of miR-655-3p predicts worse clinical outcome in patients suffering from hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2017;21:748–752.

[36] Zhang B, Sun YF, Zhang XM, et al. TUG1 weakens the sensitivity of acute myeloid leukemia cells to cytarabine by regulating miR-655-3p/CCND1 axis. Eur Rev Med Pharmacol Sci. 2020;24:4940–4953.

[37] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408.

[38] Zhou XQ, Chang YZ, Zhu LR, et al. LINC00839/miR-144-3p/WTAP (WT1 Associated protein) axis is involved in regulating hepatocellular carcinoma progression. Bioengineered. 2021;12:10849–10861.

[39] Tang Q, Chen Z, Zhao L, et al. Circular RNA hsa_circ_0000515 acts as a miR-326 sponge to promote cervical cancer progression through up-regulation of ELK1. Aging (Albany NY). 2019;11:9982–9999.

[40] Kumar P, Nagarajan A, and Uchil PD. Analysis of cell viability by the MTT assay. Cold Spring Harb Protoc. 2018;20183 469–471.

[41] Kim B. Western Blot Techniques. Methods Mol Biol. 2017;1606:133–139.

[42] Telford WG. Multiparametric analysis of apoptosis by flow cytometry. Methods Mol Biol. 2018;1678:167–202.

[43] Zhao W, Geng D, Li S, et al. LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMG2 axis in breast cancer. Cancer Med. 2018;7:842–855.

[44] Dong H, Diao H, Zhao Y, et al. Overexpression of matrix metalloproteinase-9 in breast cancer cell lines remarkably increases the cell malignancy largely via activation of transforming growth factor beta/Smad signalling. Cell Prolif. 2019;52:e12633.

[45] Pittayapruk P, Meephansan J, Prapapan O, et al. Role of matrix metalloproteinases in photocarcinogenesis. Int J Mol Sci. 2016;17:868.

[46] McMahon CM, Luger SM. Relapsed T cell ALL: current approaches and new directions. Curr Hematol Malig Rep. 2019;14:83–93.

[47] Huang X, Huang L, Xie Q, et al. LncRNAs serve as novel biomarkers for diagnosis and prognosis of childhood ALL. Biomark Res. 2021;9:45.

[48] Wallaert A, Durinck K, Van Loocke W, et al. Long noncoding RNA signatures define oncogenic subtypes in T-cell acute lymphoblastic leukemia. Leukemia. 2016;30:1927–1930.

[49] Ghafoouri-Fard S, Mohammad-Rahimi H, Taheri M. The role of long non-coding RNAs in the pathogenesis of thyroid cancer. Exp Mol Pathol. 2020;112:104332.

[50] Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–348.

[51] Duff D, Long A. Roles for RACK1 in cancer cell migration and invasion. Cell Signal. 2017;35:250–255.

[52] Cardano M, Tribioli C, Prosperi E. Targeting proliferating cell nuclear antigen (PCNA) as an effective strategy to inhibit tumor cell proliferation. Curr Cancer Drug Targets. 2020;20:240–252.

[53] Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6:99–104.

[54] Mondal S, Adhikari N, Banerjee S, et al. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: a minireview. Eur J Med Chem. 2020;194:112260.